| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3286984 | Digestive and Liver Disease Supplements | 2011 | 4 Pages |
Abstract
In western countries, about 10–25% of patients undergoing liver transplantation (LT) are HBsAg carriers. In Asia, HBV-related liver disease is the leading indication to LT. After surgery hepatitis B can develop in patients transplanted for HBV-related disease or in HBsAg-negative recipients of anti-HBc positive grafts. In the last years prophylaxis with HBIG and/or antivirals has been proposed in both conditions with excellent results. However, lack of efficacy of prophylaxis is frequently associated with the selection of HBV mutants resistant to the different drugs.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
